Why the study?
Does adjunctive cilostazol reduce platelet reactivity in patients with stable coronary artery disease on dual antiplatelet therapy?
Population
79 patients with stable coronary artery disease on dual antiplatelet therapy, divided by high on-clopidogrel…
Comparison
Adjunctive cilostazol therapy vs Placebo
Design
Cohort, randomized, double-blind, double-dummy
Authors
Loading...
Hypothesis-generating for adjunctive cilostazol in stable CAD on DAPT with HPR or diabetes; prospective RCTs needed to assess clinical benefit.
Does adjunctive cilostazol reduce platelet reactivity in patients with stable coronary artery disease on dual antiplatelet therapy?
Adjunctive cilostazol enhances platelet inhibition in stable CAD patients on DAPT, particularly in those with high on-treatment platelet reactivity and diabetes.
Capranzano et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: